Biocon Ltd.

Financial

	Biocon	Concord Biotech	Advanced Enzyme
Operational Metrics
Pharmaceutical Sector
Domestic Sales Growth - YoY	7.7 %	n/a	n/a
R&D as a % of Total Sales	7.0 %	2.26 %	7.5 %
Financials
5 yr Average ROE	7.26 %	20.02 %	12.01 %
5yr average Equity Multiplier	2.52	1.26	1.16
5yr Average Asset Turnover Ratio	0.35	0.52	0.42
5yr Avg Net Profit Margin	8.25 %	30.81 %	24.34 %
Price to Book	1.97	12.18	2.52
P/E	42.12	59.41	27.36
5yr Avg Cash Conversion Cycle	-144.7 Days	37.41 Days	87.24 Days
Inventory Days	93.33 Days	80.96 Days	72.86 Days
Days Receivable	119.85 Days	111.87 Days	58.11 Days
Days Payable	264.09 Days	173.13 Days	50.65 Days
5yr Average Interest Coverage Ratio	12.09	137.55	54.91
5yr Avg ROCE	7.9 %	25.59 %	16.0 %
5yr Avg Operating Profit Margin	19.41 %	42.97 %	38.48 %
5 yr average Debt to Equity	0.67	0.04	0.02
5yr CAGR Net Profit	6.45 %	12.77 %	0.61 %
5yr Average Return on Assets	3.07 %	15.93 %	10.35 %
Shareholdings
Promoter Holding	60.64 %	44.08 %	43.08 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	0.0	-9.62 %
Change in Mutual Fund Holding (3 Yrs)	5.25 %	-0.42 %	-1.1 %

Business

	Biocon	Concord Biotech	Advanced Enzyme
Product Wise Break-Up	Product Wise Break-Up Biosimilars 54.39 Generics 23.13 Syngene (Research Services) 22.48 Novel 0 Branded Formulations 0 Biologics 0 Formulations 0 API - Fermentation based 0 Specialized Manufacturing 0 Bio-process 0 Animal nutrition 0 Human nutrition 0	Product Wise Break-Up Branded Formulations 0 Human nutrition 0 Biologics 0 Novel 0 Bio-process 0 Formulations 16.0 Animal nutrition 0 Syngene (Research Services) 0 Specialized Manufacturing 0 API - Fermentation based 84.0 Biosimilars 0 Generics 0	Product Wise Break-Up Branded Formulations 0 Human nutrition 64.0 Biologics 0 Novel 0 Bio-process 16.0 Formulations 0 Animal Health 12.0 Syngene (Research Services) 0 Specialized Manufacturing 8.0 API - Fermentation based 0 Biosimilars 0 Generics 0
Location Wise Break-Up	Location Wise Break-Up USA 43.75 Ireland 23.83 Rest of the World 21.52 India 10.9 Asia (Ex India) 0 Europe 0	Location Wise Break-Up Europe 0 USA 0 Asia (Ex India) 0 Rest of the World 44.0 India 56.0 Ireland 0	Location Wise Break-Up Europe 5.0 USA 37.0 Asia Pacific 9.0 Rest of the World 0 India 46.0 Ireland 0 Others 3.0
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Asset Break-Up	Asset Break-Up Biosimilars 74.61 Generics 13.98 Research 11.41 Novel Biologics 0 India 0 USA 0 Europe 0	Asset Break-Up Europe 0 USA 0 Novel Biologics 0 Research 0 India 99.74 Biosimilars 0 Generics 0 Others 0.26	Asset Break-Up Europe 9.0 USA 43.57 Novel Biologics 0 Research 0 India 47.43 Biosimilars 0 Generics 0

Biocon Ltd.

SIGN UP FOR FREE